208 related articles for article (PubMed ID: 28178031)
1. Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.
Taghavi T; St Helen G; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2017 Apr; 27(4):143-154. PubMed ID: 28178031
[TBL] [Abstract][Full Text] [Related]
2. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
3. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.
Wassenaar CA; Conti DV; Das S; Chen P; Cook EH; Ratain MJ; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):94-104. PubMed ID: 25277794
[TBL] [Abstract][Full Text] [Related]
4. Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.
Murphy SE; Sipe CJ; Choi K; Raddatz LM; Koopmeiners JS; Donny EC; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1093-1099. PubMed ID: 28264876
[No Abstract] [Full Text] [Related]
5.
Sipe CJ; Koopmeiners JS; Donny EC; Hatsukami DK; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2020 Aug; 29(8):1673-1678. PubMed ID: 32532831
[TBL] [Abstract][Full Text] [Related]
6. The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
Bloom AJ; von Weymarn LB; Martinez M; Bierut LJ; Goate A; Murphy SE
Pharmacogenet Genomics; 2013 Dec; 23(12):706-16. PubMed ID: 24192532
[TBL] [Abstract][Full Text] [Related]
7. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.
Chen G; Giambrone NE; Dluzen DF; Muscat JE; Berg A; Gallagher CJ; Lazarus P
Cancer Res; 2010 Oct; 70(19):7543-52. PubMed ID: 20876810
[TBL] [Abstract][Full Text] [Related]
8. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Chen G; Giambrone NE; Lazarus P
Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
[TBL] [Abstract][Full Text] [Related]
9. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.
Berg JZ; von Weymarn LB; Thompson EA; Wickham KM; Weisensel NA; Hatsukami DK; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1423-31. PubMed ID: 20501767
[TBL] [Abstract][Full Text] [Related]
10. Influence of UGT2B10 Genotype on Urinary Excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N-glucuronide by African American Smokers.
Murphy SE; von Weymarn LB; Parenteau M; Stepanov I; Tiirikainen M; LeMarchand L; Park SL
Chem Res Toxicol; 2018 Mar; 31(3):168-175. PubMed ID: 29460622
[TBL] [Abstract][Full Text] [Related]
11. Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies.
Giratallah HK; Chenoweth MJ; Addo N; Ahluwalia JS; Cox LS; Lerman C; George TP; Benowitz NL; Tyndale RF
Drug Alcohol Depend; 2021 Jun; 223():108708. PubMed ID: 33873029
[TBL] [Abstract][Full Text] [Related]
12. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.
Berg JZ; Mason J; Boettcher AJ; Hatsukami DK; Murphy SE
J Pharmacol Exp Ther; 2010 Jan; 332(1):202-9. PubMed ID: 19786624
[TBL] [Abstract][Full Text] [Related]
13. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.
Murphy SE; Park SS; Thompson EF; Wilkens LR; Patel Y; Stram DO; Le Marchand L
Carcinogenesis; 2014 Nov; 35(11):2526-33. PubMed ID: 25233931
[TBL] [Abstract][Full Text] [Related]
14. Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance.
Liakoni E; Tyndale RF; Jacob P; Dempsey DA; Addo N; Benowitz NL
Pharmacogenet Genomics; 2021 Jul; 31(5):97-107. PubMed ID: 33675323
[TBL] [Abstract][Full Text] [Related]
15. Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Perez-Paramo YX; Watson CJW; Chen G; Thomas CE; Adams-Haduch J; Wang R; Khor CC; Koh WP; Nelson HH; Yuan JM; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):54-65. PubMed ID: 36252563
[TBL] [Abstract][Full Text] [Related]
16. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
17. Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.
Murphy SE
Chem Res Toxicol; 2017 Jan; 30(1):410-419. PubMed ID: 28092945
[TBL] [Abstract][Full Text] [Related]
18. Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.
Benowitz NL; St Helen G; Dempsey DA; Jacob P; Tyndale RF
Pharmacogenet Genomics; 2016 Jul; 26(7):340-50. PubMed ID: 27035242
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.
Taghavi T; Novalen M; Lerman C; George TP; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):882-891. PubMed ID: 29853480
[No Abstract] [Full Text] [Related]
20. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.
Chen G; Blevins-Primeau AS; Dellinger RW; Muscat JE; Lazarus P
Cancer Res; 2007 Oct; 67(19):9024-9. PubMed ID: 17909004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]